N-acetylcysteine Plus Deferoxamine for Patients With Hypotension

Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude81 enrolled

Overview

Oxidative stress is associated with kidney damage in several different situations, including hypotension. In animal models it has been shown that the combination of n-acetylcysteine plus deferoxamine is superior to its isolate use in the treatment of several diseases. Thus the investigators aimed to determine if the administration of n-acetylcysteine plus deferoxamine could prevent renal failure in critical ill patients who develops hypotension.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Hypotension Acute Renal Failure

Interventions

N-acetylcysteine and deferoxamineDRUG

N-acetylcysteine bolus dose of 50mg/kg/4h, by a manutention of 100mg/kg/day during 2 days and deferoxamine single dose of 1g administered 15mg/kg/h.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients admitted to the ICU * Presenting hypothesion (MAP \< 60mm Hg or the needing to use vasoactive drugs) for at least 30 min in the last 12h before study inclusion Exclusion Criteria: * Age lower than 18 years old * Chronic renal failure * A known history of allergy to any of the study drugs * Using n-acetylcysteine to paracetamol overdose * Pregnant women * Patients who used iodinated contrast medium * Hemoglobin less than 6.5 mg/dl * Cancer patients

Locations (1)

São José Hospital

Criciúma, Santa Catarina, Brazil

Outcomes

Primary Outcomes

Development of acute renal failure

Time frame: 28 days

Secondary Outcomes

28 day-mortality

Time frame: 28 days

Decrease on plasma oxidative damage and inflammatory parameters

Time frame: at the end of drug infusion

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.